Milestone Pharmaceuticals (MIST) Expected to Announce Quarterly Earnings on Wednesday

Milestone Pharmaceuticals (NASDAQ:MIST) will likely be issuing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of $0.19 per share and revenue of $30.1150 million for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Friday, March 20th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $1.44 million during the quarter, compared to analyst estimates of $37.52 million. On average, analysts expect Milestone Pharmaceuticals to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Milestone Pharmaceuticals Stock Performance

Shares of Milestone Pharmaceuticals stock opened at $1.90 on Tuesday. The company has a debt-to-equity ratio of 1.37, a current ratio of 8.01 and a quick ratio of 7.96. The firm has a market cap of $227.32 million, a P/E ratio of -2.41 and a beta of 1.04. The firm has a 50 day simple moving average of $1.70 and a 200 day simple moving average of $1.93. Milestone Pharmaceuticals has a fifty-two week low of $1.00 and a fifty-two week high of $3.06.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MIST. Wall Street Zen upgraded Milestone Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Raymond James Financial began coverage on Milestone Pharmaceuticals in a research report on Friday, April 10th. They set a “strong-buy” rating and a $6.00 target price for the company. Finally, Zacks Research downgraded Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $7.50.

Insider Transactions at Milestone Pharmaceuticals

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 36,500 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $2.26, for a total value of $82,490.00. Following the transaction, the chief executive officer directly owned 446,244 shares of the company’s stock, valued at approximately $1,008,511.44. This trade represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Pathstone Holdings LLC acquired a new stake in shares of Milestone Pharmaceuticals during the third quarter worth $2,000,000. Creative Planning increased its stake in shares of Milestone Pharmaceuticals by 74.6% in the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after acquiring an additional 10,000 shares during the last quarter. Orbimed Advisors LLC bought a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter valued at about $6,444,000. Marshall Wace LLP increased its stake in shares of Milestone Pharmaceuticals by 289.8% in the 4th quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock valued at $3,347,000 after acquiring an additional 1,231,793 shares during the last quarter. Finally, Two Sigma Investments LP bought a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter valued at about $1,333,000. 86.18% of the stock is owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.